|
Market Closed -
Other stock markets
|
After hours 20:00:00 | |||
| 131.28 USD | -1.09% |
|
130.50 | -0.59% |
| 07-30 | Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials | RE |
| 07-28 | Atea Pharmaceuticals Says Combination Drug Meets Endpoints in Phase 3 Hepatitis C Trial | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 157.15 | +18.4% | 27 | ||||||
| 1,276.96 | +5.53% | 26 | ||||||
| 270.59 | +1.91% | 22 | ||||||
| 268.68 | +2.04% | 28 | ||||||
| 363.92 | +0.61% | 18 | ||||||
| 153.99 | -2.65% | 21 | ||||||
| 212.36 | +21.71% | 22 | ||||||
| 317.2 | -6.17% | 24 | ||||||
| 357.03 | -7.9% | 29 | ||||||
| 28.75 | +14.31% | 26 | ||||||
| 62.96 | -0.22% | 24 | ||||||
| 557.12 | +15.27% | 24 | ||||||
| 96.14 | +20.29% | 23 | ||||||
| 21.42 | +6.7% | 20 | ||||||
| 9,686.67 | +37.03% | 15 | ||||||
| 6,318.94 | +8.07% | 16 | ||||||
| 54.92 | +15.15% | 18 | ||||||
| 80.33 | +49.07% | 15 | ||||||
| 4.142 | +9.1% | 17 | ||||||
| 41.2 | +18.7% | 10 | ||||||
| Average | 1,016.52 | +11.35% | 21 | ||||||
| Weighted average by Cap. | 696.5 | +6.01% | 24 |
- Stock Market
- Stocks
- GILD Stock
- Sector Gilead Sciences, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
